Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03146663 · ClinicalTrials.gov registry record · Phase 2
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
A Phase 2 study, sponsored by NuCana.
- Terminated
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT03146663 is a Phase 2 study that was terminated before completion, run by NuCana. The registered enrollment target is 53 participants.
The verdict
NCT03146663, a Phase 2 study, was terminated before completion, sponsored by NuCana.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
This study was designed to evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer. The primary objective was to determine the anti-tumor activity of NUC-1031 at the selected dose level (500 mg/m2 or 750 mg/m2).
Interventions
- DRUG NUC-1031 500 mg
- DRUG NUC-1031 750mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2017-09-28 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03146663
The ClinicalTrials.gov registry entry for NCT03146663 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NuCana, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NUC-1031 500 mg is the first listed.
NCT03146663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03146663 about?
NCT03146663 is a clinical study titled "NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer". This study was designed to evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer. The primary objective was to determine the anti-tumor activity of NUC-1031 at the selected dose level (500 mg/m2 or 750 mg/m2).
What is the current status of trial NCT03146663?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2017-09-28. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03146663?
The interventions under investigation include: NUC-1031 500 mg (DRUG), NUC-1031 750mg (DRUG).
Who is sponsoring clinical trial NCT03146663?
This trial is sponsored by NuCana, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.